Biomarkers /
NTRK1
Overview
NTRK1 (neurotrophic tyrosine kinase, receptor, type 1) encodes the high affinity nerve growth factor receptor protein. NTRK1 fusions have been observed in colorectal cancer (PMID: 2869410), papillary thyroid cancer (PMID: 19883730), lung cancer (PMID: 24162815), glioblastoma (PMID: 19883730; PMID: 24647444), and cholangiocarcinoma (PMID: 24563076). NTRK1 fusions trigger constitutive TRKA kinase activity (PMID: 24162815), which activates cell growth and differentiation pathways (PMID: 12652644).
NTRK1 is altered in 2.72% of all cancers with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, cutaneous melanoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in NTRK1 are NTRK1 Mutation (1.86%), NTRK1 Amplification (0.48%), NTRK1 Fusion (0.16%), NTRK1 R214W (0.04%), and NTRK1-LMNA Fusion (0.04%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of NTRK1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.